Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFX-01 in Subarachnoid Haemorrhage
NCT02614742Phase 2Completed
- Sponsor
- TheraCryf
- Start
- Apr 2016
- Primary completion
- Sep 2019
- Modality
- Biodegradable Polymers, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sulforadex in subarachnoid hemorrhage (SAH), sponsored by TheraCryf. Started Apr 2016; status: completed.
02
Drugs
sulforadex
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT02614742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614742.